Benzinga
Published Apr 19, 2024 16:00
Updated Apr 19, 2024 17:10
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Eli Lilly and Co (NYSE:LLY) in comparison to its major competitors within the Pharmaceuticals industry. By analyzing critical financial metrics, market position, and growth potential, our objective is to provide valuable insights for investors and offer a deeper understanding of company's performance in the industry.
Eli Lilly and Co Background Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Eli Lilly and Co | 128.61 | 65.84 | 19.75 | 19.91% | $3.03 | $7.57 | 28.1% |
Novo Nordisk A/S | 46.31 | 36.11 | 16.69 | 22.01% | $28.51 | $55.85 | 36.95% |
Merck & Co Inc | 894.50 | 8.44 | 5.31 | -3.11% | $-0.77 | $10.72 | 5.78% |
AstraZeneca PLC | 35.88 | 5.41 | 4.66 | 2.52% | $2.18 | $9.72 | 7.29% |
Novartis AG | 22.58 | 4.05 | 4.15 | 19.99% | $4.18 | $8.75 | 7.39% |
Pfizer Inc | 68.62 | 1.62 | 2.45 | -3.62% | $-1.77 | $6.69 | -41.34% |
Sanofi SA | 19.89 | 1.44 | 2.31 | -0.75% | $0.42 | $8.15 | 6.5% |
Bristol-Myers Squibb Co | 12.51 | 3.33 | 2.23 | 6.03% | $4.45 | $8.73 | 0.62% |
GSK PLC | 13.17 | 4.84 | 2.14 | 2.64% | $1.16 | $5.63 | 9.16% |
Zoetis Inc | 30.20 | 14 | 8.28 | 10.42% | $0.83 | $1.49 | 8.48% |
Takeda Pharmaceutical Co Ltd | 36.21 | 0.95 | 1.54 | 1.53% | $314.89 | $731.71 | 1.33% |
Viatris Inc | 222.20 | 0.64 | 0.87 | -3.7% | $-0.07 | $1.6 | -1.0% |
Dr Reddy's Laboratories Ltd | 18.94 | 3.69 | 3.64 | 5.29% | $22.42 | $42.2 | 6.57% |
Jazz Pharmaceuticals PLC | 17.91 | 1.82 | 2.05 | 2.61% | $0.29 | $0.9 | 4.1% |
Corcept Therapeutics Inc | 24.13 | 4.65 | 5.25 | 6.43% | $0.03 | $0.13 | 31.39% |
Average | 104.5 | 6.5 | 4.4 | 4.88% | $26.91 | $63.73 | 5.94% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } By closely studying Eli Lilly and Co, we can observe the following trends:
The debt-to-equity (D/E) ratio assesses the extent to which a company relies on borrowed funds compared to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Eli Lilly and Co against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.